Friday 18th, November
Thoracic Oncology Forum
Metastatic NSCLC: New updates
Session Chairs: Shadi Alkhayyat | Marwan Al Hejili
09:00
Opening remarks
Ahmed Allehebi
09:10
1st Line Options of EGFR Positive Mets NSCLC (exon 19del , exon 21 (L858R) & 20)
Waleed Alghareeb
09:30
2nd Line Options of EGFR Positive Mets NSCLC
Samah Alrehaily
09:50
Optionsin 1st and Lines of ALK-1 Positive Mets NSCLC
Marwan Al Hejili
10:10
Optionsin ROS-1 , RET , RAS & MET-14 Skipping Positive Mets NSCLC
Ahmed Allehebi
10:30
Is there a Role of Immunotherapy in Driver’s Positive Mets NSCL
Hamed Al Husaini
10:50
Panel Discussion Q&A
11:00
Industrial Symposia
11:30 – 13:30
Break / Lunch
Practice changing evidence of locally advanced NSCLC
Session Chairs: Jamal Zekri | Ramzi Addass
13:30
Role of MDT in the Management of NSCLC
Mervat Mahrous
13:50
Updates to the Role of Durvalumab After CCRT
Ahmed Allehebi
14:10
Radiation Therapy in Stage III NSCLC
Ameen Al-Omair
14:30
Optimizing Treatment Decisions in Stage III NSCLC
Turki Al Faye
14:50
Panel Discussion Q&A
15:00 – 15:30
Coffee Break
Early stage NSCLC: Management updates
Session Chairs: Khaled Al Kattan | Salem Alshehri
15:30
Role of Adjuvant TKI in Early NSCLC
Turki Al Faye
15:50
Role of Immunotherapy in Early NSCLC
Ahmed Refae
16:10
Surgical Approach in Case of N2 Disease (NSCLC)
Ahmed Jamjoom
16:30
New Data for Neoadjuvant options in NSCLC
Shadi Alkhayyat
16:50
Panel Discussion Q&A
17:00
Industrial Symposium
17:30
TOF – Closing Remarks